- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.01. | Inhibikase hits pause on Parkinson's program over efficacy as it prioritizes lung drug | ||
| 29.01. | Fewer than 1% of clinical trials in the US include pregnant patients, study finds | ||
| 29.01. | Two hormone therapies restore normal sleep in mouse models of amyotrophic lateral sclerosis | ||
| 29.01. | Stryker to spin off spinal implant business, as Viscogliosi Brothers-owned VB Spine | ||
| 29.01. | OS Therapies pays $8M for full IP rights to its lead drug, gains 2 more cancer assets in the process | ||
| 29.01. | Zimmer Biomet nets foot-and-ankle specialist Paragon 28 for $1.1B | ||
| 29.01. | I-Mab lays off 27% of workforce after pivoting to CLDN18.2 bispecific | ||
| 29.01. | Cullinan plans approval application for lung cancer drug this year based on phase 2 win | ||
| 29.01. | Zentalis lays off 40% of staff to fund registrational trial of WEE1 drug | ||
| 28.01. | Imperative Care claims FDA green light for its largest large-bore stroke catheter | ||
| 28.01. | CROs should brace for continued slow Big Pharma R&D spending: analyst | ||
| 28.01. | Using decentralized trials improves patient diversity, industry-backed study finds | ||
| 28.01. | Judge rules in favor of Aurion in IPO suit, a decision investor Alcon plans to appeal | ||
| 28.01. | Philips zaps emergency AED business over to Bridgefield Capital | ||
| 28.01. | Tris builds clinical case for opioid alternative by showing its pain drug is less likely to be abused | ||
| 28.01. | BioAge axes obesity asset over liver toxicity, pivots to preclinical prospects | ||
| 28.01. | Versant launches another obesity biotech with $65M series A and 'clinic-ready' GIP antibody | ||
| 28.01. | Leap crashes as midphase data mark end of gastric cancer program | ||
| 28.01. | Takeda regains home rights to phase 3-ready depression drug from Neurocrine | ||
| 27.01. | Cell therapy biotech Aurion eyes IPO despite legal pushback from investor | ||
| 27.01. | FDA's diagnostics CMO named interim agency commissioner | ||
| 27.01. | Metsera eyes $289M IPO to fund phase 3 weight loss trial | ||
| 27.01. | After White House transition, FDA's diversity guidance for clinical trials no longer available | ||
| 27.01. | Author Siddhartha Mukherjee, LinkedIn co-founder Reid Hoffman connect to launch AI drug design startup | ||
| 27.01. | Maze Therapeutics rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
